Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients
Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the safety and efficacy of intravenous (IV) infusion of
Ang (1-7) compared to placebo with respect to time to recovery, disease severity, need for
mechanical ventilation or extracorporeal membrane oxygenation (ECMO), and mortality in
patients with COVID 19.